Logo

Epoch Biosciences and Celera Diagnostics Expand Licensing Agreement for Probe Technologies

May 20, 2004

NEW YORK, May 20 (GenomeWeb News) - Epoch Biosciences has expanded its licensing agreement with Celera Diagnostics for two of its probe technologies, Epoch said today.

 

The amended agreement expands Celera's rights to include Epoch's minor groove binder technology, MGB, and its quencher technology, Dark Quencher, into selected infectious disease products.

 

Epoch first licensed the technology to Celera in January.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.